Drugs / Autologous CoNS-AM+
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03158012 Comparator | Apr 2016 → Dec 2017 | atopic eczema | University of California, San Diego | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CoNS-AM+ | “Autologous CoNS-AM+ was isolated from swabs that were obtained from the nonlesional skin of each patient with AD, expanded by culture, and then reapplied topically to the...” PMID 34132739 ↗ Jun 2021 |
| Modality | Other / unclassified | “The data from this randomized clinical trial suggest that bacteriotherapy with an autologous strain of skin commensal bacteria can safely decrease S aureus colonization and...” PMID 34132739 ↗ Jun 2021 |
| Route | Topical | “Autologous CoNS-AM+ was isolated from swabs that were obtained from the nonlesional skin of each patient with AD, expanded by culture, and then reapplied topically to the...” PMID 34132739 ↗ Jun 2021 |